Summary Intermittent fasting is more than just a diet
Next steps: FDA decision (REDEFINE-1 & 2) expected late 2026 REDEFINE-11 (2.4/2.4 mg) readout in H1 2027 Higher-dose Phase 3 initiation planned H2 2026 Why It Matters: The obesity market is now a high-efficacy battleground, with GLP-1 and dual incretin therapies redefining standards of care
The methodology included: Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America Product mapping across short-acting GLP-1 agonists, long-acting GLP-1 agonists, dual-action therapies (GLP-1/GIP), and emerging tri-agonist candidates Analysis of reported and modeled annual revenues specific to GLP-1 drug portfolios Coverage of manufacturers representing 75-80% of global market share in 2024 Extrapolation using bottom-up (prescription volume ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across drug type (short-acting, long-acting, dual-action), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), indication (type 2 diabetes, obesity, cardiovascular diseases), and administration route (subcutaneous injection, oral, inhalation) Download Free Sample Kindly complete the form below to receive a free sample of this Report This is really good guys
Ultimately, Bjerre Knudsen of Novo Nordisk and Richard DiMarchi of Indiana Unviersity were verified as the individuals who shaped this critical expansion
Night Shred GLP-1 activates your bodys natural 'anti-hunger' hormone, enhancing the production of GLP-1 through a unique blend of ingredients that work synergistically to curb cravings and promote a feeling of fullness
